Novel combinations for the treatment of metastatic breast cancer

Por Vahdat, Linda T.
Publicado em 2010

Microenvironmental regulation of epithelial-mesenchymal transitions in cancer

Por Gao, Dingcheng, Vahdat, Linda T., Wong, Stephen, Chang, Jenny C., Mittal, Vivek
Publicado em 2012

Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression

Por Gao, Dingcheng, Nolan, Daniel, McDonnell, Kevin, Vahdat, Linda, Benezra, Robert, Altorki, Nasser, Mittal, Vivek
Publicado em 2009

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

Por Twelves, Chris, Cortes, Javier, Vahdat, Linda, Olivo, Martin, He, Yi, Kaufman, Peter A., Awada, Ahmad
Publicado no Breast Cancer Res Treat (2014)

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

Por Twelves, Chris, Cortes, Javier, Vahdat, Linda, Olivo, Martin, He, Yi, Kaufman, Peter A., Awada, Ahmad
Publicado no Breast Cancer Res Treat (2015)

High-Grade KIT-Negative Sarcoma of the Small Bowel in a Patient With Chronic Myeloid Leukemia Receiving Long-Term Tyrosine Kinase Inhibitors

Por Martz, Josef, Jain, Sarika, Vahdat, Linda T., Qin, Lihui, Mosquera, Juan Miguel, Antonescu, Cristina R., Popa, Elizabeta C.
Publicado em 2013

Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studie...

Por O’Shaughnessy, Joyce, McIntyre, Kristi, Schwartzberg, Lee, Wilks, Sharon, Puhalla, Shannon, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado no Springerplus (2015)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurr...

Por Puhalla, Shannon, Wilks, Sharon, Brufsky, Adam M, O’Shaughnessy, Joyce, Schwartzberg, Lee S, Berrak, Erhan, Song, James, Vahdat, Linda
Publicado no Breast Cancer (Dove Med Press) (2016)

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

Por Vahdat, Linda T., Garcia, Agustin A., Vogel, Charles, Pellegrino, Christine, Lindquist, Deborah L., Iannotti, Nicholas, Gopalakrishna, Prashanth, Sparano, Joseph A.
Publicado em 2013

Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device

Por Galletti, Giuseppe, Sung, Matthew S., Vahdat, Linda T., Shah, Manish A., Santana, Steven M., Altavilla, Giuseppe, Kirby, Brian J., Giannakakou, Paraskevi
Publicado em 2013

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado em 2014

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Por McIntyre, Kristi, O’Shaughnessy, Joyce, Schwartzberg, Lee, Glück, Stefan, Berrak, Erhan, Song, James X., Cox, David, Vahdat, Linda T.
Publicado no Breast Cancer Res Treat (2014)

Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer

Por Muss, Hyman, Cortes, Javier, Vahdat, Linda T., Cardoso, Fatima, Twelves, Chris, Wanders, Jantien, Dutcus, Corina E., Yang, Jay, Seegobin, Seth, O’Shaughnessy, Joyce
Publicado em 2014

Remodeling of the Methylation Landscape in Breast Cancer Metastasis

Por Reyngold, Marsha, Turcan, Sevin, Giri, Dilip, Kannan, Kasthuri, Walsh, Logan A., Viale, Agnes, Drobnjak, Marija, Vahdat, Linda T., Lee, William, Chan, Timothy A.
Publicado em 2014

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients

Por Ebenezer, Gigi J, Carlson, Karen, Donovan, Diana, Cobham, Marta, Chuang, Ellen, Moore, Anne, Cigler, Tessa, Ward, Maureen, Lane, Maureen E, Ramnarain, Anita, Vahdat, Linda T, Polydefkis, Michael
Publicado no Ann Clin Transl Neurol (2014)

Breast Cancer Subtypes in Asian-Americans Differ According to Asian Ethnic Group

Por Chuang, Ellen, Christos, Paul, Flam, Arielle, McCarville, Katherine, Forst, Melissa, Shin, Sandra, Vahdat, Linda, Swistel, Alexander, Simmons, Rache, Osborne, Michael, Moore, Anne, Mazumdar, Madhu, Klein, Paula
Publicado em 2012

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

Por Vahdat, Linda T., Thomas, Eva S., Roché, Henri H., Hortobagyi, Gabriel N., Sparano, Joseph A., Yelle, Louise, Fornier, Monica N., Martín, Miguel, Bunnell, Craig A., Mukhopadhyay, Pralay, Peck, Ronald A., Perez, Edith A.
Publicado em 2012

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity

Por Stanton, Sasha E, Ward, Maureen M, Christos, Paul, Sanford, Rachel, Lam, Christina, Cobham, Marta V, Donovan, Diana, Scheff, Ronald J, Cigler, Tessa, Moore, Anne, Vahdat, Linda T, Lane, Maureen E, Chuang, Ellen
Publicado no BMC Cancer (2015)

Activation of hematopoietic stem/progenitor cells promotes immunosuppression within the pre-metastatic niche

Por Giles, Amber Jin, Reid, Caitlin Marie, Evans, Justin DeWayne, Murgai, Meera, Vicioso, Yorleny, Highfill, Steven Lorenz, Kasai, Miki, Vahdat, Linda, Mackall, Crystal Lee, Lyden, David, Wexler, Leonard, Kaplan, Rosandra Natasha
Publicado no Cancer Res (2015)

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and...

Por Andreopoulou, Eleni, Vigoda, Ivette S., Valero, Vicente, Hershman, Dawn L., Raptis, George, Vahdat, Linda T., Han, Hyo S., Wright, John J., Pellegrino, Christine M., Cristofanilli, Massimo, Alvarez, Ricardo H., Fehn, Karen, Fineberg, Susan, Sparano, Joseph A.
Publicado em 2013